Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes         Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 T1D in adult and pediatric patients aged eight years and older, with stage 2 T1D compared to placeboAdditional regulatory reviews are ongoing across different disease stages by regulatory authorities around the world Paris, September 10, 2025- The Chinese National Medical Products Admi ...

Metsera, Inc. (NASDAQ:MTSR) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 28, Bank of America Securities analyst Tim Anderson raised the firm’s price target on Metsera, Inc. (NASDAQ:MTSR) from $45 to $50, while maintaining a Buy rating on the stock. The improved bullish sentiment for the stock comes after the company reported financial and business updates for its fiscal second quarter of 2025. The company reported notable progress in its obesity and metabolic ...

Venture Global, Inc. (NYSE:VG) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 27, Christopher Robertson from Deutsche Bank upgraded Venture Global, Inc. (NYSE:VG) from a Hold to a Buy rating with a $17 price target. The analyst noted that Deutsche Bank visited the management at the Plaquemines LNG facility. During the visit, the firm was able to gain a clearer picture of the complexity and discipline of the company to simultaneously continue commissioning and co ...

Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 3, Eric Schmidt FCA from Cantor Fitzgerald reiterated a Buy rating on Avidity Biosciences, Inc. (NASDAQ:RNA) with a price target of $96. The reiterated Buy rating on the stock comes after the company reported strong business updates in its fiscal second quarter of 2025. The company reported progress in three late-stage neuromuscular programs for treating Duchenne muscular dy ...

Applied Digital Corporation (NASDAQ:APLD) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 29, Applied Digital Corporation (NASDAQ:APLD) announced finalizing a new lease agreement with CoreWeave for an additional 150MW of data center capacity at Applied Digital’s Polaris Forge 1 Campus in Ellendale. This new lease increases the total contracted lease revenue for the company to around $11 billion, including $7 billion from two earlier leases signed earlier in May 2 ...

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 3, Bradley Canino from Guggenheim initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT) with a Buy rating and a $40 price target. The analyst noted that they liked the stock when it was trading at $3 as the market overlooked an important upcoming progression-free survival readout for its drug Ivonescimab in direct comparison to Merck’s Pembrolizumab in lung cancer. No ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 2, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) with a price target of $80. The analyst noted the company’s recent deal with Novartis as a strong vote of confidence. The deal brings $200 million upfront, which has the potential to lead to a $2 billion milestone. Trucchio highlighted that this deal valid ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 4, Citizens JMP analyst Ivan Tuerkcan initiated coverage of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) with a $41 price target. The firm started coverage of the company after it announced enrolling the first patient with non-small cell lung cancer (NSCLC) in its Phase 1/2 clinical trial. This trial tests a combination of IDE397, a potential first-in-class MAT2A inhibitor, and Tr ...

MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 21, Leerink Partners analyst Thomas Smith reiterated a Buy rating on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a price target of $73. Smith highlighted the potential of the company’s Sonelokimab in treating moderate-to-severe hidradenitis suppurativa. He noted that the upcoming Phase 3 VELA trial results to be a key catalyst for the stock and believes that it will show ...

TransMedics Group, Inc. (NASDAQ:TMDX) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On August 4, TransMedics Group, Inc. (NASDAQ:TMDX) received conditional approval from the US FDA for its Investigational Device Exemption, allowing the company to start its Next-Generation OCS ENHANCE Heart trial. The trial has two parts, where the first part focuses on supporting prolonged heart perfusion using the OCS Heart System. Whereas the second part aims to prove that OCS Heart pe ...